KF
AERI

Krilogy Financial’s Aerie Pharmaceuticals AERI Stock Holding History

Krilogy Financial’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$6K – 733
2018
Q3 		$6K Buy
+100
New +$6.43K ﹤0.01% 608
2018
Q2 		– Sell
-100
Closed -$5K – 672
2018
Q1 		$5K Hold
100
– – ﹤0.01% 611
2017
Q4 		$6K Hold
100
– – ﹤0.01% 583
2017
Q3 		$5K Hold
100
– – ﹤0.01% 666
2017
Q2 		$5K Sell
100
-100
-50% -$4.66K ﹤0.01% 600
2017
Q1 		$8K Hold
200
– – ﹤0.01% 543
2016
Q4 		$8K Hold
200
– – ﹤0.01% 543
2016
Q3 		$8K Buy
+200
New +$4.41K ﹤0.01% 554

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Krilogy Financial's AERI Position: Q4 2018 in Review

Krilogy Financial sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 100 shares — an estimated $6K sold.

Krilogy Financial first reported a position in AERI in Q3 2016 and held it in 8 quarters. The position peaked at $8K in Q1 2017. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

  • Krilogy Financial reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 100 Aerie Pharmaceuticals shares in Q4 2018, an estimated $6K.
  • Krilogy Financial first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 8 quarters.
  • Krilogy Financial's Aerie Pharmaceuticals position peaked at $8K in Q1 2017.
  • 160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.